| MIR-106a-5p functions as a tumor suppressor during the development of astrocytomas by targeting FASTK. | astrocytomas, |
| miR-106a* might play an anti-oncogenic role in esophageal carcinoma by regulating CACUL1 expression, which suggest miR-106a* as a new potential diagnostic and therapeutic target for esophageal carcinoma. | esophageal, |
| miR-106a-5p may function as a tumor suppressor in osteosarcoma cells via regulating expression of its target gene RUNX1. | osteosarcoma, |
| These studies provide support for a pro-oncogenic role of the miR-106a~363 cluster in Ewing Sarcoma. | sarcoma, |
| miR-106a has an oncogenic role in pancreatic tumorigenesis by promoting cancer cell proliferation, epithelial-mesenchymal transition and invasion by targeting tissue inhibitors of metalloproteinase 2 (TIMP-2). | pancreatic, |
| expression of TIMP2 was inversely associated with miR-106a in nodule tissues. Apoptotic body was also seen under electron microscope accompanied by silencing of miR-106a. Together, this data indicated that miR-106a may act as an oncogene and contribute to gastric cancer development. | gastric, |
| MIRN106 microRNA, human. MiR-106a as an oncogene could promote proliferation and metastasis of prostate cancer cells by directly targeting PTEN in vivo and in vitro | prostate, |